These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24288037)

  • 1. Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.
    Francis JS; Markov V; Leone P
    J Inherit Metab Dis; 2014 May; 37(3):369-81. PubMed ID: 24288037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
    Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
    Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
    Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
    J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
    Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
    J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
    Becker I; Wang-Eckhardt L; Eckhardt M
    J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
    von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
    Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspartoacylase supports oxidative energy metabolism during myelination.
    Francis JS; Strande L; Markov V; Leone P
    J Cereb Blood Flow Metab; 2012 Sep; 32(9):1725-36. PubMed ID: 22617649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
    Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
    Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirecting
    Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
    JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
    Baslow MH; Guilfoyle DN
    Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
    Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
    J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canavan disease: a white matter disorder.
    Kumar S; Mattan NS; de Vellis J
    Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
    Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
    Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease.
    Kirmani BF; Jacobowitz DM; Kallarakal AT; Namboodiri MA
    Brain Res Mol Brain Res; 2002 Nov; 107(2):176-82. PubMed ID: 12487123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination.
    Mattan NS; Ghiani CA; Lloyd M; Matalon R; Bok D; Casaccia P; de Vellis J
    Neurobiol Dis; 2010 Nov; 40(2):432-43. PubMed ID: 20637282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model.
    Clarner T; Wieczorek N; Krauspe B; Jansen K; Beyer C; Kipp M
    J Mol Neurosci; 2014 May; 53(1):22-30. PubMed ID: 24272958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary treatment proposed for Canavan's disease.
    Chen V
    Lancet Neurol; 2005 May; 4(5):273. PubMed ID: 15861552
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
    Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM
    J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease.
    Namboodiri AM; Moffett JR; Arun P; Mathew R; Namboodiri S; Potti A; Hershfield J; Kirmani B; Jacobowitz DM; Madhavarao CN
    Adv Exp Med Biol; 2006; 576():145-63; discussion 361-3. PubMed ID: 16802710
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease.
    Kumar S; Biancotti JC; Matalon R; de Vellis J
    J Neurosci Res; 2009 Nov; 87(15):3415-27. PubMed ID: 19739253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.